Abstract: The present invention relates to a composition comprising a GLP-1/GLP-2 dual agonist for use in a method for the treatment and/or prevention of diarrhea, loose stools, urgency, incontinence, high fecal output and/or high stomal output in a patient having undergone surgical resection of the bowel.

Abstract: In one aspect, exendin-4 derivative compositions are provided. In some embodiments, unit dose forms and kits containing such compositions are also provided. In some embodiments, such compositions are useful for treatment of hyperinsulinemic hypoglycemia.

Abstract: The present invention relates to a pharmaceutical combination comprising a PCSK9 inhibitor and a GLP-1 receptor agonist; The invention also relates to the use of the pharmaceutical combination in preparing drugs for treating hyperglycemia, diabetes, obesity and/or cholesterol related diseases.

Abstract: The present invention concerns the use of aprotic polar solvents, water, and an ionization stabilizing agent to prepare device compatible stable therapeutic formulations by dissolving a therapeutic agent (active ingredient) in an aprotic polar solvent system that can then be used with various devices (e.g., pumps, infusion sets) for administration of the formulation. In certain embodiments, the invention is directed to formulations comprising one or more therapeutic agents, as well as methods of making such formulations, comprising at least one therapeutic agent dissolved in an aprotic polar solvent system, such as a DMSO/water admixture, comprising at least one ionization stabilizing excipient in a concentration sufficient to impart physical and chemical stability to the therapeutic agent.

Abstract: The present invention relates to semaglutide for use in weight management.

Abstract: The present invention relates to a method for treating gastrointestinal bleeding in a subject with severe von Willebrand Disease comprising administering to the subject at least one dose of recombinant von Willebrand Factor (rVWF) ranging from about 40 IU/kg to about 100 IU/kg, wherein the first dose further comprises recombinant Factor VIII (rFVIII).

Abstract: The present invention relates to fibronectin-based scaffold domain proteins that bind to myostatin. The invention also relates to the use of these proteins in therapeutic applications to treat muscular dystrophy, cachexia, sarcopenia, osteoarthritis, osteoporosis, diabetes, obesity, COPD, chronic kidney disease, heart failure, myocardial infarction, and fibrosis. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the proteins.

Abstract: The present invention relates to a hydrolyzed collagen powder having specific characteristics, a. process for its preparation and uses thereof, in therapy and so on.

Abstract: Lactoferrin (Lf) is used in the prophylaxis and treatment of Alzheimer's disease (AD), and is used as an active agent in the preparation of drugs for preventing or treating AD. By designing an in vitro model of AD, it has been proved that Lf can reduce the cell damage caused by A?, and play the role of anti-Alzheimer's disease by improving the anti-inflammatory ability, inhibiting the inflammation and regulating apoptosis. Meanwhile, using the APP/PS1 transgenic mouse model, it has been confirmed that Lf can reduce the phosphorylation level of Tau protein, shorten the time for mice to escape from the water maze, and improve learning and cognitive functions.

Abstract: Provided herein are methods and compositions for treating Parkinson's disease (PD), or alleviating symptoms thereof, by the enhancing expression of aromatic acid decarboxylase (AADC) in the substantia nigra. In particular, the beneficial effects of levodopa to subjects suffering from PD are extended by enhancing the expression of AADC in the substantia nigra of the subject.

Abstract: This disclosure relates to mRNA therapy for the treatment of propionic acidemia. mRNAs for use in the invention, when administered in vivo, encode propionyl-CoA carboxy lase alpha (PCCA) and propionyl-CoA carboxy lase beta (PCCB). mRNA therapies of the disclosure increase and/or restore deficient levels of PCCA and/or PCCB expression and/or activity in subjects.

Abstract: This invention is directed to vaccine compositions and methods of using the same to prevent infection.

Abstract: The present invention relates to compositions, immunogenic or vaccine compositions and pharmaceutical compositions for the prevention or treatment of urticaria of equine mammals, preferably of horses. Furthermore, the invention provides methods for preventing or treating urticaria of equine mammals, preferably of horses.

Abstract: A composition for treating type 1 diabetes mellitus autoimmunity can include a therapeutically effective amount of two or more overlapping fragments of preproinsulin and a pharmaceutically acceptable carrier, wherein at least one of the polypeptide fragments is antigenic.

Abstract: Described herein are methods and compositions for directing an antibody response in a subject away from one or more first epitopes of an antigen (e.g., immunodominant epitopes of a vaccine antigen) and towards one or more second epitopes of the antigen by administering one or more antibodies targeting the one or more first epitopes of the antigen.

Abstract: The present invention relates to methods, polypeptides and compositions of said polypeptides and/or their encoding nucleic acids for the prophylactic vaccination and/or therapeutic treatment of cancer, and the use of polypeptides in treating and/or preventing cancer, and/or improving the therapeutic efficacy of agents for the treatment of cancer.

Abstract: The present invention provides universal immunotherapy compositions useful for targeted treatment of cancers.

Abstract: A bioconjugate of an E. coli glucosylated O4 antigen polysaccharide covalently linked to a carrier protein and compositions thereof are provided. Also provided are recombinant host cells for producing the bioconjugate, and methods of producing the bioconjugate using the recombinant host cells. The recombinant host cells contain a nucleic acid encoding a glucosyl transferase capable of modifying the E. coli O4 antigen with glucose branching to produce the glucosylated O4 antigen polysaccharide. Bioconjugates of an E. coli glucosylated O4 antigen polysaccharide described herein can be used alone or in combination with one or more additional E. coli O-antigen polysaccharides to induce antibodies against an E. coli glucosylated antigen, and to vaccinate a subject against extra-intestinal pathogenic E. coli (ExPEC).

Abstract: The present invention relates to a composition comprising a) recombinant exosporium-producing Bacillus cells that express a fusion protein comprising: (i) at least one plant growth stimulating protein or peptide and (ii) a targeting sequence that localizes the fusion protein to the exosporium of the Bacillus cells; and b) at least one particular fungicide disclosed herein in a synergistically effective amount. Furthermore, the present invention relates to the use of this composition as well as a method for enhancing plant growth, promoting plant health, and/or reducing overall damage of plants and plant parts.

Abstract: The present invention is directed to virus-like particles (VLPs) which display immunogenic peptides of Flavivirus non-structural Protein 1 (NS1) derived from Dengue Virus (DENY), immunogenic compositions and vaccines against Flavivirus infection and related methods of immunizing and/or vaccinating subjects against Flavivirus, especially Dengue infections. The VLPs according to the present invention comprise polypeptide subunits of Dengue NS 1 protein which has been conjugated to the surface of a VLP as described herein, often a VLP derived from a Qbeta (P?) or AP205 bacteriophage.

Abstract: The present invention relates to vaccine compositions comprising Norovirus antigens and adjuvants, in particular, mixtures of monovalent VLPs and mixtures of multivalent VLPs, and to methods of conferring protective immunity to Norovirus infections in a human subject.

Abstract: Disclosed herein are vaccine compositions, in particular, polyvalent icosahedral compositions for antigen presentation. The disclosed compositions may contain an S particle made up of recombinant fusion proteins. The recombinant fusion proteins may include a norovirus (NoV) S domain protein, a linker protein domain operatively connected to the norovirus S domain protein, and an antigen protein domain operatively connected to said linker.

Abstract: Compositions useful as poliovirus immunogens are provided along with methods and compositions for preparing the same. Compositions comprising poliovirus immunogens can enable a host response that includes virus-neutralizing antibodies which can protect the host from infection and/or disease.

Abstract: Provided herein are vaccine compositions including recombinant protein antigens derived from computationally optimized broadly reactive influenza antigen (COBRA) proteins and an immunomodulator, and methods of use thereof. The vaccine compositions include one or more COBRA proteins, and the immunomodulator is a cationic lipid. The cationic lipid includes R-DOTAP. The methods of use of the vaccine compositions includes methods of inducing a humoral immune response against influenza viruses, methods of inducing polyfunctional CD8+ and CD4+ effector T cells against influenza viruses, methods of inducing memory T cells against influenza viruses, methods of enhancing immunity against influenza viruses, and methods of inducing balanced Th1/Th2 immune response against influenza viruses in a subject.

Abstract: The present disclosure relates to a chimeric influenza virus hemagglutinin (HA) polypeptide, comprising one or more stem domain sequence, each having at least 60% homology with a stem domain consensus sequence of H1 subtype HA (H1 HA) and/or H5 subtype HA (H5 HA), fused with one or more globular head domain sequence, each having at least 60% homology with a globular head domain consensus sequence of H1 subtype HA (H1 HA) or H5 subtype HA (H5 HA).

Abstract: The present invention relates to an attenuated mumps virus and a live vaccine comprising the same. The attenuated mumps virus vaccine of the present invention can be effectively used for additional vaccination to control the occurrence of breakthrough infection and the epidemic of mumps due to differences in genotypes of existing vaccine strains and epidemic strains and decreased immunity.

Abstract: An object of the present invention is to establish means for providing a component vaccine which can selectively or intensively induce cell-mediated immunity mainly attributable to MHC class I, and humoral immunity mainly attributable to MHC class II. The inventors have found that the object can be attained by providing a component vaccine containing, as an active ingredient, a trimer and/or a hexamer of a molecular needle carrying a peptide binding to MHC class I and/or a peptide binding to MHC class II. The inventors have also found an information acquisition method that can determine the MHC class or the like of a test peptide or a similar substance by detecting a change in secretion of a physiologically active substance such as a cytokine in a test animal which has been infected with a target microorganism.

Abstract: The present invention relates to an extracellular vesicle including a coronavirus-derived antigen protein or a gene encoding the protein, and a use of the extracellular vesicle. According to the present invention, when mice are immunized by administering an activated immune cell-derived extracellular vesicle loaded with an antigen protein or mRNA, excellent antigen-specific neutralizing antibody production and T cell response induction effects are confirmed. When the extracellular vesicle is stored under room-temperature and refrigerated conditions after freeze-drying, high stability and an excellent antibody production effect are experimentally confirmed.

Abstract: The present invention relates to a protein subunit vaccine comprising at least one antigen characterized in that it comprises at least one monomer from at least one variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), wherein the at least one monomer is selected from the group consisting of the S1 subunit of the Spike protein or the receptor-binding domain (RBD) of the Spike protein. In an aspect of the present invention, the protein subunit vaccine comprises at least one antigen characterized in that it comprises two monomers from at least one variant of SARS-CoV-2, wherein each of the monomers are selected from the group consisting of the S1 subunit or RBD protein, and wherein the monomers are chemically bound to each other, optionally through a linker, forming fusion dimers or non-fusion dimers. The protein subunit vaccine may further comprise at least an adjuvant and at least an immunostimulant.

Abstract: The present invention relates to a plant-based COVID-19 variant recombinant spike protein expression vector, and a recombinant protein using the expression vector, wherein a plant expression system is used such that the recombinant protein does not have the disadvantages of animal-derived recombinant proteins and exhibits an excellent SARS coronavirus 2 prevention and treatment effect, and thus can be effectively utilized as a safe composition for preventing and treating COVID-19.

Abstract: Disclosed herein are mosaic coronavirus (MoCoV) spike(S) proteins or antigenic fragments thereof. Also disclosed herein are nucleic acid constructs comprising one or more nucleic acid sequences encoding a MoCoV S protein or antigenic fragment thereof. Also disclosed herein are coronavirus vaccine vectors comprising one or more polynucleotides encoding a MoCoV S protein or antigenic fragment thereof. Also disclosed herein are coronavirus vaccines comprising one or more MoCoV S proteins or antigenic fragments thereof and one or more carriers. Also disclosed herein are pharmaceutical compositions, host cells, and kits comprising one or more of the MoCoV S proteins or antigenic fragments thereof, nucleic acid constructs, coronavirus vaccine vectors, and/or coronavirus vaccines.

Abstract: The present disclosure provides immunogenic compositions comprising HCV E1, E2, or E1/E2 polypeptides from two or more different HCV genotypes. The present disclosure provides immunogenic compositions comprising HCV E2 or E1/E2 polypeptides from two or more different HCV genotypes. The immunogenic compositions are useful in carrying out methods of inducing an immune response to HCV. The present disclosure further provides methods of stimulating an immune response to HCV in an individual.

Abstract: The present invention relates to a composition comprising proteins identified in barn dust extract or peptides derived from one of the proteins. The composition is useful in the prevention or treatment of a disease.

Abstract: Disclosed herein are methods of forming compounds and exemplary compounds in the nature of a conjugated compound demonstrating enhanced stability, which in some embodiments comprises a protein and virus particle mixed in a conjugation reaction to form a conjugate mixture, such that the conditions and steps of forming these products allow for unrefrigerated storage for longer time periods than previous approaches, thus making feasible access to such products over a global supply chain.

Abstract: A novel composite, and research on the preparation, application and the like of the composite. The method for preparing the composite comprises: contacting a polyinosinic-polycytidylic acid, at least one cationic stabilizer, and a soluble calcium salt in a liquid reaction system, the cationic stabilizer being a water-soluble non-antibiotic amino compound having a molecular weight of less than or equal to 5 kDa, or a graft copolymer formed by a water-soluble non-antibiotic amino compound and one or more of methoxypolyethylene glycol, polyethylene glycol, polyethylenimine, folic acid, or galactose. The composite has moderate viscosity and molecular weight, is convenient to use in pharmaceutical application, has stable chemical properties, is not easy to be degraded in long-term storage, and is safe to use.

Abstract: It has been discovered that PIK3? (PIK3delta) selectively modulates the activation and proliferation of natural Tregs. Methods of modulating immune responses by modulating PIK3? bioavailability or biological activity are provided.

Abstract: A method of inducing a Type I interferon response in a mammalian subject that presents with a microbial infection, cancerous tumor or hematological malignancy that comprises administering an amount of a halogenated xanthene as discussed above, effective to induce the Type I interferon response. A method of enhancing a mammalian immunogen-specific immune response that comprises contacting mammalian cells, in vivo or present in a mammalian cell growth supporting medium, with an adjuvant-effective amount of a halogenated xanthene, and an immunogen to which that response is to be enhanced. A mammalian HX compound-adjuvanted vaccine composition that contains an immunogen present in a vaccine-effective amount along with an adjuvant-effective amount of a halogenated xanthene (HX) compound and one or more excipients present at about 0.001% by weight to 10% by weight of the vaccine composition dissolved or dispersed in a pharmaceutically acceptable diluent.

Abstract: This disclosure provides a system for preventing or reducing side effects in a patent undergoing immunotherapy to remove diseased cells that express a target antigen: for example, by CAR T cell therapy. Side effects can ensue from concurrent depletion of hematopoietic cells bearing the same target antigen. A population of engineered hematopoietic cells is prepared by obtaining healthy hematopoietic cells from the patient or a third party donor, and using them to produce engineered hematopoietic cells. The engineered cells either do not express the target antigen, express it at a lower density, or express it in a modified form. The engineered hematopoietic cells are formulated for administration to the patient, whereupon they reconstitute hematopoietic cell function, thereby preventing or reducing the side effects.

Abstract: The present invention relates to the treatment of cancer, in particular to the treatment of cancer using a HLA-A2/MAGE-A4×CD3 bispecific antibody and a 4-1BB (CD137) agonist.

Abstract: Described herein is a method comprising (a) reconstituting a lyophilized formulation comprising a polypeptide, a saccharide, a surfactant, and a buffer, with a diluent comprising an aromatic alcohol, a phenolic compound, or an amino acid with aromatic side chain, and (b) administering the reconstituted formulation to a subject in need thereof within 12 hours of reconstitution, wherein the polypeptide is a bispecific antibody construct, such as a bispecific antibody construct that binds human DLL3 and human CD3 and optionally comprises the amino acid sequence of SEQ ID NO: 75 and SEQ ID NO: 9.

Abstract: The present invention pertains to compositions and methods of making high concentration protein formulations of a therapeutic protein.

Abstract: The present disclosure provides, inter alia, methods and compositions for differentiation of pluripotent stem cells and derived hematopoietic lineage cells including hemogenic endothelial cells, hematopoietic progenitor cells and natural killer cells. The differentiation efficiency for the hemogenic endothelial cells, the hematopoietic progenitor cells and the natural killer cells can be improved by using the methods and compositions of this disclosure described herein.

Abstract: Human iPSC-derived macrophages, methods for the manufacture thereof, and methods of treatment of cancer and other conditions therewith. Human iPSC-derived macrophages further comprise a chimeric antigenic receptor (CAR) expressed thereon, such as Bai1, MegF10 or MerTK, referred to as iPSC-derived CAR-expressing macrophages (iPSC-CARMAs). The methods of treatment provide further co-administering to the subject an effective amount of iPSC-CARMAs and an antibody specific for the cancer, such as anti-CD47 or anti-EGFR antibody. The iPSC-derived macrophages promote phagocytic activity, reduce tumor burden, and improve subject survival.

Abstract: Disclosed herein are engineered cells and/or hypoimmunogenic cells including engineered cells and/or hypoimmunogenic stem cells, engineered cells and/or hypoimmunogenic cells differentiated therefrom, and engineered cells and/or hypoimmunogenic CAR-T cells (primary or differentiated from engineered and/or hypoimmunogenic stem cells) and related methods of their use and generation comprising reduced expression of one or more Y chromosome genes and reduced expression of MHC I and/or MHC II human leukocyte antigen molecules and overexpression of CD47. Provided herein are cells further exhibiting reduced expression of T-cell receptors.

Abstract: Provided herein are vectors comprising a polycistronic expression casstte comprising a polynucleotide that encodes a CD 19 specific chimeric antigen receptor, a polynucleotide that encodes a cytokine, and a polynucleotide that encodes a marker protein, wherein the polynucleotide that encodes the CD 19-specific chimeric antigen receptor and the polynucleotide that encodes the cytokine coding sequence are separated by a polynucleotide sequence that comprises an F2A element, and wherein the polynucleotide sequence that encodes the cytokine and the polynucleotide sequence that encodes the marker protein are separated by a polynucleotide sequence that comprises a T2A element.

Abstract: The present disclosure relates to bicistronic polypeptide constructs for use in allogeneic gene therapy, for example, CAR-T cell therapy. The bicistronic constructs comprise first polynucleotide encoding a therapeutic molecule (e.g., a CAR-T or an antibody) and a second polynucleotide encoding an Immune Surveillance Masking Molecule (ISMM). The ISMM comprises a human leukocyte antigen-E genetically fused to a non-functional version, e.g., a fragment, of the protein knock-out by the insertion of the bicistronic construct, e.g., beta-2 microglobulin or B2M. Also provided are vectors comprising the bicistronic constructs, cells (e.g., CAR-T cells), and methods of use. Also provided are kits and articles of manufacture. The present disclosure also provides four novel insertion sites that can be used to insert an expression construct in the B2M gene.

Abstract: An immune effector cell expressing an exogenously introduced p40 subunit of IL-12; an exogenously introduced ligand of CCR7 (such as CCL-19 and CCL-21); and a functional exogenous receptor (such as a chimeric antigen receptor) comprising an extracellular antigen binding domain, a transmembrane domain, and an intracellular signaling domain.

Abstract: A probe capable of inducing destruction of actin fibers in a spatiotemporally selective manner, and a method using the probe. A compound represented by the following Formula (I) or a salt thereof. R1 may represent, when present, the same or different monovalent substituents present on a benzene ring; R2 may represent a bromine atom or an iodine atom; m may be an integer of 0 to 4; and n may be an integer of 1 or 2.

Abstract: It is an object of the present invention to provide a medicament for killing tumor cells, having few side effects. According to the present invention, provided is a medicament for killing tumor cells, comprising: a conjugate of a substance that binds to a target substance on the surface of tumor cells and a cytotoxin; and a glycosylated chlorin derivative or a pharmaceutically acceptable salt thereof.

Abstract: Unpurified or low pure soy phosphatidylserine is used to make cochleates. The cochleates contain about 40-74% soy phosphatidylserine, a multivalent cation and a biological active. A preferred cochleate contains the antifungal agent amphotericin B.